- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4/A Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 10.16 EX-10.16(A)
- 10.16 EX-10.16(B)
- 10.17 EX-10.17(A)
- 10.17 EX-10.17(B)
- 10.17 EX-10.17(C)
- 10.17 EX-10.17(D)
- 10.18 EX-10.18
- 10.19 EX-10.19(A)
- 10.19 EX-10.19(B)
- 10.19 EX-10.19(C)
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23(A)
- 10.23 EX-10.23(B)
- 10.23 EX-10.23(C)
- 10.23 EX-10.23(D)
- 10.24 EX-10.24(A)
- 10.24 EX-10.24(B)
- 10.24 EX-10.24(C)
- 23.4 EX-23.4
- 23.5 EX-23.5
- 99.1 EX-99.1
- 99.9 EX-99.9
- 99.10 EX-99.10
- 99.11 EX-99.11
- 99.12 EX-99.12
- 99.13 EX-99.13
- Download Excel data file
- View Excel data file
- 8 Feb 21 424B3 Prospectus supplement
- 4 Feb 21 EFFECT Notice of effectiveness
- 20 Jan 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 21 Dec 20 S-4/A Registration of securities issued in business combination transactions (amended)
-
25 Nov 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 2 Oct 20 S-4 Registration of securities issued in business combination transactions
Exhibit 23.5
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of NTN Buzztime, Inc. on Amendment No.1 to Form S-4 of our report dated April 24, 2020, with respect to our audits of the financial statements of Brooklyn Immunotherapeutics, LLC (Successor) and IRX Therapeutics, Inc. (Predecessor) (the “Company”) as of December 31, 2019 and 2018 and for the year ended December 31, 2019 and for the period of November 6, 2018 through December 31, 2018 (Successor), and the period from January 1, 2018 through November 5, 2018 (Predecessor), which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum llp
Marcum llp
New York, NY
November 24, 2020